Bayer Schering Pharma initiates Phase III program of lung drug
Bayer Schering Pharma has initiated a Phase III program with its oral agent riociguat. The two studies - Chest-1 and Patent-1 - will investigate the efficacy and safety of riociguat in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. Over 700 patients will be recruited for the two studies.